Supernus epilepsy drug secures label expansion

Supernus Pharmaceuticals has picked up an expected supplemental approval for Oxtellar XR as a monotherapy in the treatment of partial-onset seizures in adults and in children aged six and older. Oxtellar XR is an oral, once-daily drug previously approved for adjunctive therapy in this setting.